Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $8.00 by Analysts at Guggenheim

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective lowered by Guggenheim from $12.00 to $8.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts have also recently weighed in on the stock. Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research report on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $3.05 on Friday. The firm has a 50 day simple moving average of $3.42 and a 200-day simple moving average of $5.33. Zentalis Pharmaceuticals has a 1-year low of $2.66 and a 1-year high of $18.07. The stock has a market cap of $217.34 million, a price-to-earnings ratio of -1.22 and a beta of 1.74.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. Equities analysts expect that Zentalis Pharmaceuticals will post -2.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Anfield Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $40,000. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at $37,000. Paloma Partners Management Co acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth $37,000. Aigen Investment Management LP acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth $41,000. Finally, Kennedy Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals during the 1st quarter worth $189,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.